Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS) is a progressively debilitating disease characterized by selective neurodegeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. Degeneration of upper and lower motor neurons leads to spasticity and atrophy respect...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Iran University of Medical Sciences
2022-06-01
|
| Series: | Neurology Letters |
| Subjects: | |
| Online Access: | https://www.neurologyletters.com/article_151620_874d70c85a317a1bc94f0368ccacaf43.pdf |
| _version_ | 1797630561450196992 |
|---|---|
| author | Fardin Nabizadeh |
| author_facet | Fardin Nabizadeh |
| author_sort | Fardin Nabizadeh |
| collection | DOAJ |
| description | Amyotrophic Lateral Sclerosis (ALS) is a progressively debilitating disease characterized by selective neurodegeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. Degeneration of upper and lower motor neurons leads to spasticity and atrophy respectively, which begins with focal weakness and then spread to other muscles including the diaphragm, and finally died as a result of respiratory paralysis. To date, there are only two drugs approved by US Food and Drug Administration (FDA) for ALS treatment: riluzole and edaravone. The approval of only two drugs is evident of minimal progress in ALS treatment over the past decades. However, more drugs are currently under investigation, and we hope more drugs will be available for ALS treatment, but many challenges in developing new therapeutic agents may remain such as blood-brain barrier (BBB), targeting, clearance, biostability, and degradation. Advances in biomaterial proposed utilizing nanoparticles to package and delivery pharmaceuticals to CNS to protect against absorption, clearance, and facilitate the transportation across BBB. Designing and engineering nano-bio materials loaded with agents such as riluzole or other efficient substances provide prospective advances in therapeutic approaches and drug delivery systems for neurodegenerative disease, particularly ALS. Here we reviewed biomaterials used in ALS therapeutic approach over the last years. |
| first_indexed | 2024-03-11T11:09:53Z |
| format | Article |
| id | doaj.art-dd5878c2338248e78ddf9f23634251cf |
| institution | Directory Open Access Journal |
| issn | 2821-1723 |
| language | English |
| last_indexed | 2024-03-11T11:09:53Z |
| publishDate | 2022-06-01 |
| publisher | Iran University of Medical Sciences |
| record_format | Article |
| series | Neurology Letters |
| spelling | doaj.art-dd5878c2338248e78ddf9f23634251cf2023-11-12T09:10:00ZengIran University of Medical SciencesNeurology Letters2821-17232022-06-0111121610.52547/nl.1.1.12151620Biomaterials in The Treatment of Amyotrophic Lateral SclerosisFardin Nabizadeh0School of Medicine, Iran University of Medical Sciences, Tehran, IranAmyotrophic Lateral Sclerosis (ALS) is a progressively debilitating disease characterized by selective neurodegeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. Degeneration of upper and lower motor neurons leads to spasticity and atrophy respectively, which begins with focal weakness and then spread to other muscles including the diaphragm, and finally died as a result of respiratory paralysis. To date, there are only two drugs approved by US Food and Drug Administration (FDA) for ALS treatment: riluzole and edaravone. The approval of only two drugs is evident of minimal progress in ALS treatment over the past decades. However, more drugs are currently under investigation, and we hope more drugs will be available for ALS treatment, but many challenges in developing new therapeutic agents may remain such as blood-brain barrier (BBB), targeting, clearance, biostability, and degradation. Advances in biomaterial proposed utilizing nanoparticles to package and delivery pharmaceuticals to CNS to protect against absorption, clearance, and facilitate the transportation across BBB. Designing and engineering nano-bio materials loaded with agents such as riluzole or other efficient substances provide prospective advances in therapeutic approaches and drug delivery systems for neurodegenerative disease, particularly ALS. Here we reviewed biomaterials used in ALS therapeutic approach over the last years.https://www.neurologyletters.com/article_151620_874d70c85a317a1bc94f0368ccacaf43.pdfamyotrophic lateral sclerosisriluzolebiomaterialsnanoparticles |
| spellingShingle | Fardin Nabizadeh Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis Neurology Letters amyotrophic lateral sclerosis riluzole biomaterials nanoparticles |
| title | Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis |
| title_full | Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis |
| title_fullStr | Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis |
| title_full_unstemmed | Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis |
| title_short | Biomaterials in The Treatment of Amyotrophic Lateral Sclerosis |
| title_sort | biomaterials in the treatment of amyotrophic lateral sclerosis |
| topic | amyotrophic lateral sclerosis riluzole biomaterials nanoparticles |
| url | https://www.neurologyletters.com/article_151620_874d70c85a317a1bc94f0368ccacaf43.pdf |
| work_keys_str_mv | AT fardinnabizadeh biomaterialsinthetreatmentofamyotrophiclateralsclerosis |